X @The Economist

“By raising reimbursements for new drugs while increasing the use of cheaper generic therapies, Europe could spur more investment in lifesaving R&D and defuse Donald Trump’s mutually destructive pricing push,” argues Tomas Philipson in a guest essay https://t.co/Na86UHJlLF ...